CDK12 and adenocarcinoma: CDK12 expression is high in some cancers and lower in some cancers, and in the case of gastric cancer, it has been observed to be downregulated, and is negatively correlated with poor outcomes, poorly differentiated adenocarcinoma, and advanced stage; therefore CDK12, could be a tumor suppressor in gastric cancer [233].